shanghai mengke pharmaceuticals

MicuRx Raises US$25m For US-China Antibiotic Clinical Trial

MicuRx Pharma has raised US$25 million in Series B financing to carry out clinical trials on its MRX-I antibiotic candidate.

Shanghai MengKe Pharma To Develop MRX-I Antibiotic For Chinese Market

MicuRx Pharma and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced a joint venture to develop MRX-I for the Chinese market.